vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and SYPRIS SOLUTIONS INC (SYPR). Click either name above to swap in a different company.
SYPRIS SOLUTIONS INC is the larger business by last-quarter revenue ($30.3M vs $19.1M, roughly 1.6× NewAmsterdam Pharma Co N.V.). SYPRIS SOLUTIONS INC runs the higher net margin — -12.9% vs -90.7%, a 77.8% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -9.5%). SYPRIS SOLUTIONS INC produced more free cash flow last quarter ($-1.5M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.
NAMS vs SYPR — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $30.3M |
| Net Profit | $-17.4M | $-3.9M |
| Gross Margin | — | 4.6% |
| Operating Margin | -186.1% | -10.9% |
| Net Margin | -90.7% | -12.9% |
| Revenue YoY | 740.1% | -9.5% |
| Net Profit YoY | 55.5% | -2992.6% |
| EPS (diluted) | $-0.15 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $30.3M | ||
| Q3 25 | — | $28.7M | ||
| Q2 25 | $19.1M | $31.4M | ||
| Q1 25 | — | $29.5M | ||
| Q4 24 | $12.8M | $33.4M | ||
| Q3 24 | $29.1M | $35.7M | ||
| Q2 24 | — | $35.5M | ||
| Q1 24 | — | $35.6M |
| Q4 25 | — | $-3.9M | ||
| Q3 25 | — | $517.0K | ||
| Q2 25 | $-17.4M | $-2.1M | ||
| Q1 25 | — | $-899.0K | ||
| Q4 24 | $-92.2M | $135.0K | ||
| Q3 24 | $-16.6M | $390.0K | ||
| Q2 24 | — | $16.0K | ||
| Q1 24 | — | $-2.2M |
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | — | 8.2% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | — | 8.1% |
| Q4 25 | — | -10.9% | ||
| Q3 25 | — | -6.1% | ||
| Q2 25 | -186.1% | -4.6% | ||
| Q1 25 | — | -0.4% | ||
| Q4 24 | -338.5% | 3.9% | ||
| Q3 24 | -85.9% | 4.8% | ||
| Q2 24 | — | 3.6% | ||
| Q1 24 | — | -3.9% |
| Q4 25 | — | -12.9% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | -90.7% | -6.5% | ||
| Q1 25 | — | -3.0% | ||
| Q4 24 | -721.7% | 0.4% | ||
| Q3 24 | -57.2% | 1.1% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | -6.2% |
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $0.02 | ||
| Q2 25 | $-0.15 | $-0.09 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | $-0.91 | $0.00 | ||
| Q3 24 | $-0.18 | $0.02 | ||
| Q2 24 | — | $0.00 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $778.5M | $17.8M |
| Total Assets | $815.1M | $107.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $739.2M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $834.2M | — | ||
| Q3 24 | $422.7M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $17.8M | ||
| Q3 25 | — | $20.0M | ||
| Q2 25 | $778.5M | $18.7M | ||
| Q1 25 | — | $19.0M | ||
| Q4 24 | $757.5M | $19.6M | ||
| Q3 24 | $378.9M | $18.2M | ||
| Q2 24 | — | $19.0M | ||
| Q1 24 | — | $20.8M |
| Q4 25 | — | $107.8M | ||
| Q3 25 | — | $112.5M | ||
| Q2 25 | $815.1M | $105.8M | ||
| Q1 25 | — | $110.2M | ||
| Q4 24 | $864.6M | $119.4M | ||
| Q3 24 | $439.2M | $121.6M | ||
| Q2 24 | — | $124.2M | ||
| Q1 24 | — | $129.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $-1.1M |
| Free Cash FlowOCF − Capex | $-37.8M | $-1.5M |
| FCF MarginFCF / Revenue | -197.2% | -5.0% |
| Capex IntensityCapex / Revenue | 0.5% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | $-6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.1M | ||
| Q3 25 | — | $-178.0K | ||
| Q2 25 | $-37.7M | $1.1M | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | $-37.5M | $2.3M | ||
| Q3 24 | $-12.5M | $-4.8M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | — | $-1.5M | ||
| Q3 25 | — | $-390.0K | ||
| Q2 25 | $-37.8M | $941.0K | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | $-37.5M | $1.9M | ||
| Q3 24 | $-12.6M | $-4.9M | ||
| Q2 24 | — | $6.0M | ||
| Q1 24 | — | $-2.0M |
| Q4 25 | — | -5.0% | ||
| Q3 25 | — | -1.4% | ||
| Q2 25 | -197.2% | 3.0% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | -293.5% | 5.7% | ||
| Q3 24 | -43.2% | -13.8% | ||
| Q2 24 | — | 16.8% | ||
| Q1 24 | — | -5.7% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | 0.5% | 0.5% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | 0.0% | 1.2% | ||
| Q3 24 | 0.3% | 0.4% | ||
| Q2 24 | — | 0.5% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | -12.21× | ||
| Q2 24 | — | 385.25× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NAMS
Segment breakdown not available.
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
